RxDoctor Payments Data

Bobbi Bullock

Family · Nampa, IDNPI 1669620506

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $419,426 of the $609,350 with a category attached, or 68.8%. AbbVie accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $209,673 and has fallen 77.2% since, to $47,834 in 2025. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$609,350in general payments, 2019–2025

Across 1,010 payments — averaging $603.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$609K
  • Galderma Laboratories, L.p.$405
  • Revance Therapeutics, Inc.$49

What the payments were for

  • Consulting fees$90,90115%
  • Speaking & faculty fees$419,42669%
  • Travel & lodging$73,69212%
  • Food & beverage$25,1744%
  • Education$1560%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)1,002$608,896
Galderma Laboratories, L.p.6$405
Revance Therapeutics, Inc.2$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$609,350 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.

See all family providers in Idaho →

Other family in Nampa

See the full list for Idaho →

Where these figures come from

Is this you, or does something look wrong? →